The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Oct. 28, 6:10 AM

Slide #2. Abeona Therapeutics Inc. Secondary Offering

Company: Abeona Therapeutics Inc. (NASDAQ:ABEO)
Date announced: 10/26/2016
Shares Offered: 6,000,000
Date of Pricing: 10/27/2016
Price Per Share: $7.00
Secondary Offering Details: Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the offering are to be sold by Abeona. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 10/27- Abeona Therapeutics Inc. (NASDAQ: ABEO), a clinical stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced the pricing of an underwritten public offering of 6,000,000 shares of common stock at a public offering price of $7.00 per share. The gross offering size for this offering is expected to be approximately $42,000,000 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 900,000 shares of common stock. The offering is expected to close on or about November 1, 2016, subject to customary closing conditions.

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening diseases. Co.'s primary programs are ABO-101 and ABO-102, adeno-associated virus-based gene therapies for Sanfilippo syndrome. Co. is also developing ABO-201 gene therapy for Juvenile Neuronal Ceroid Lipofuscinoses also known as juvenile Batten disease; and ABO-301 for Fanconi anemia disorder using a CRISPR/Cas9-based gene editing approach to gene therapy program for blood diseases. In addition, Co. is also developing plasma protein therapies including PTB-101 SDF Alpha™ (alpha-1 protease inhibitor) for inherited chronic obstructive pulmonary disease.
Open the ABEO Page at The Online Investor »

Company Name:  Abeona Therapeutics Inc
Sector:  Biotechnology
Number of ETFs Holding ABEO:  2
Total Market Value Held by ETFs:  $297593
Total Market Capitalization:  $268.00M
% of Market Cap. Held by ETFs:  0.11%

Open the ABEO Page at The Online Investor (in a new window) »

October 28, 2016    6:10 AM Eastern
Quotes delayed 20 minutes

Strong Buy (4.00 out of 4)
99th percentile
(ranked higher than approx. 99% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.